Latest News
NRx Pharmaceuticals, Inc.
- NRX Pharmaceuticals, Inc. Estimates – LS:A4091K
- NRx Pharmaceuticals Completes Manufacturing Validation for Preservative-Free Ketamine Ahead of FDA Decision
- NRx Pharmaceuticals completes manufacturing validation for preservative-free ketamine By Investing.com
- Nrx Pharmaceuticals, Inc. Completes Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
- NRx Pharmaceuticals sets Dec. 17, 2026 virtual annual meeting; submission deadlines Oct. 25–26
- NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
- NRx Pharmaceuticals Receives FDA Labeling Review Letter for Preservative-Free Ketamine
- NRX Pharmaceuticals (NRXP) Edges Higher as Shares Test $2.90 - IV Contraction
- NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital
- Radnor's NRx Pharmaceuticals Lands $11M DARPA Contract to Pair Robotic TMS With Its Depression Drug
- NRX Pharmaceuticals (NRXP) Ticks Up 1.71% to $2.92 as Shares Hold a Tight Range - Moving Average Crossovers
- NRx Pharmaceuticals (NASDAQ:NRXP) Is In A Good Position To Deliver On Growth Plans
Headlines from the last 30 days, linking to the original publishers. See all market news →